Regulatory changes, geopolitical pressures and technological advancements are among the factors currently driving new and evolving challenges within the clinical …
Verastem Oncology’s combination therapy has shown durability in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data, presented during an …
Heart failure (HF) is a substantial global health problem that is characterised by significant mortality and poor quality of life. …
ReAlta Life Sciences has secured $40m to back the continuation of a Phase II study of its lead candidate, pegtarazimod, …
Sparian Biosciences has initiated a Phase I study of SBS-147, an arylepoxamide receptor (AEAr) agonist under development for the treatment …
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral pan-rho-associated protein …
Oncology drug development has shifted decisively towards precision immunotherapies, where biomarker-defined patient populations play a pivotal role. Immuno-oncology now represents …
A mid-stage trial on Takeda’s anti-CD38 therapy, mezagitamab, has demonstrated the drug’s potential to boost platelet counts in patients with …
Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, suggesting a normalisation of …
According to the US Centers for Disease Control and Prevention, heart disease is the leading cause of death in the …
The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma have announced the activation of tinostamustine in the Glioblastoma Adaptive …
Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive …
An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has invited …
Clinical depression represents a major public health challenge whose diagnosis and treatment are frequently hindered by social stigma or patient …
Insmed is putting a stop to the development of Brinsupri (brensocatib) in hidradenitis suppurativa (HS) after the drug failed to …
